Table 2.

Circulating miRNAs for various neurodegenerative disorders

miRNAs	Sample	Approach	Method	NDD
Increased expression of miR-34a and miR-181b	PBMC	miRNA profiling	Microarray	AD
Reduced expression of miR-27a-3p	CSF	miRNA profiling	qRT-PCR	AD
60 miRNAs differentially regulated between the different Braak stages, including Let-7 family members	CSF	miRNA profiling	qRT-PCR	AD
Elevated levels of miR-146a and miR-155	CSF	Candidate miRNA	Microarray	AD
Significant increase in miR-9, miR-125b, miR-146a, miR-155	CSF	Candidate miRNA	Microarray	AD
12-miRNA signature:	Peripheral blood	miRNA profiling	NGS	AD
7-miRNA signature:	Plasma	miRNA profiling	Nanostring	AD
Elevated levels of let-7b	CSF	Candidate miRNA	qRT-PCR	AD
miR-15a associated with amyloid plaque score	Plasma	Candidate miRNA	Microarray	AD
miR-29a/b, miR-181c, and miR-9 down-regulated	Serum	Candidate miRNA	qRT-PCR	AD
Increased levels of miR-34c	PBMC	Candidate miRNA	qRT-PCR	AD
Circulating brain-enriched miRNAs: “miR‐132 family” and “miR‐134 family”	Plasma	Candidate miRNA	qRT-PCR	AD
18 significantly under-expressed miRNAs	PBMC	miRNA profiling	Microarray	PD
miR-1, miR-22-5p and miR-29 distinguish non-treated PD from healthy subjects	Total Peripheral Blood	miRNA profiling	qRT-PCR	PD
miR-16-2-3p, miR-26a-2-3p, miR30a differentiate treated from untreated patients	Total peripheral blood	miRNA profiling	qRT-PCR	PD
miR-331-5p upregulated	Plasma	miRNA profiling	qRT-PCR	PD
miR-1826, miR-450b-3p, miR-626, and miR-505	Plasma	miRNA profiling	Microarray	PD
16 miRNAs (including miR-16, miR-20a and miR-320) modified in patients pre-DBS	Leukocytes	miRNA profiling	NGS	PD
8 miRNAs (miR-451, miR-1275, miR-328, miR-638, miR-149, miR-665 and miR-338-3) significantly up- or downregulated	Leukocytes	miRNA profiling	Microarray	ALS
Expression of ALS-specific miRNA inflammatory signature	Monocytes	miRNA profiling	Microarray	ALS